Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.52 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.52 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.48 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.42 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.42 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.42 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.42 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.42 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.42 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.42 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.42 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.42 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2656136 | 1.00 | CYP1A2 (0.95) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| SCHEMBL208141 | 0.98 | — | — | |
| Water SCHEMBL28807419 | 0.95 | CYP1A2 (0.95) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| Hydrochloric Acid SCHEMBL3821044 | 0.93 | CYP1A2 (0.83) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| Hydrochloric Acid SCHEMBL4004213 | 0.91 | CYP1A2 (0.80) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| Hydrochloric Acid SCHEMBL1284223 | 0.91 | CYP1A2 (0.80) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| Hydrochloric Acid SCHEMBL3959012 | 0.91 | CYP1A2 (0.80) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| Hydrochloric Acid SCHEMBL10994303 | 0.91 | CYP1A2 (0.80) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| Hydrochloric Acid SCHEMBL7653012 | 0.91 | CYP1A2 (0.80) | CYP1A2NR1I2PGRADORA3PTGS2 | |
| Hydrochloric Acid SCHEMBL20501205 | 0.91 | CYP1A2 (0.80) | CYP1A2NR1I2PGRADORA3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115245591-B | Degradable embolism microsphere and preparation method thereof | 苏州浩微生物医疗科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-111925298-B | 4-CNAB and preparation method thereof | 无锡紫杉药业有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-115245591-A | Degradable embolism microsphere and preparation method thereof | 苏州浩微生物医疗科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-114588137-A | Application of triclosan in preparation of medicine for killing parasitic nematodes | 中国农业科学院兰州兽医研究所 | 2022-06-07 | — | — | CN | claimed |
| CN-111333641-B | Enhanced fluorescent probe for tetrazine bio-orthogonal labeling and synthesis thereof | 中国科学院大连化学物理研究所 | 2022-05-31 | — | — | CN | claimed |
| CN-111333645-B | Fluorescent probe for marking cytoskeleton | 中国科学院大连化学物理研究所 | 2021-10-15 | — | — | CN | claimed |
| CN-111925298-A | 4-CNAB and preparation method thereof | 无锡紫杉药业有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-111333641-A | Enhanced fluorescent probe for tetrazine bio-orthogonal labeling and synthesis thereof | 中国科学院大连化学物理研究所 | 2020-06-26 | — | — | CN | claimed |
| CN-111333645-A | Fluorescent probe for marking cytoskeleton | 中国科学院大连化学物理研究所 | 2020-06-26 | — | — | CN | claimed |
| CN-108864123-B | Synthetic method of stemona alkaloid | 山西大学 | 2020-04-17 | — | — | CN | claimed |
| US-6096124-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-01 | — | — | US | claimed |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| EP-4342880-B1 | IONIZABLE LIPID COMPOUND FOR NUCLEIC ACID DELIVERY AND LNP COMPOSITION THEREOF | JENKEM TECH CO LTD TIANJIN (CN) | 2025-09-10 | — | — | EP | disclosed |
| US-4446113-A | HYPOTENSIVE AGENTS | BEECHAM GROUP P.L.C. (GB) | 1984-05-01 | — | — | US | disclosed |
| EP-0093535-A1 | Novel chromenes and chromans | BEECHAM GROUP PLC (GB) | 1983-11-09 | — | — | EP | disclosed |
| EP-0076075-A1 | Pharmaceutically active benzopyran compounds | BEECHAM GROUP PLC (GB) | 1983-04-06 | — | — | EP | disclosed |
| US-4148998-A | ANTIBIOTICS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1979-04-10 | — | — | US | disclosed |
| US-4148798-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | PTGS2 1610/4885PDE4D 1809/4885GAA 3557/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | PTGS2 3480/4885PDE4D 2187/4885GAA 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.